We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
+3.88%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$10.6M
(+7.6%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
7.76%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
53
New
7
Increased
21
Reduced
13
Closed
7
Avg Time Held
4.4
quarters
Top 10 Avg Time Held
0.8
quarters
Top 20 Avg Time Held
0.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JD.com
JD
|
+$10.5M |
| 2 |
Heron Therapeutics
HRTX
|
+$2.69M |
| 3 |
TG Therapeutics
TGTX
|
+$2.69M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$2.57M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$2.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$2.78M |
| 2 |
Puma Biotechnology
PBYI
|
+$2.66M |
| 3 |
ABLX
Ablynx NV
ABLX
|
+$2.63M |
| 4 |
Travere Therapeutics
TVTX
|
+$2.57M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.63% |
| 2 | Financials | 29.15% |
| 3 | Consumer Discretionary | 10.46% |
| 4 | Industrials | 2.95% |
| 5 | Communication Services | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SAGE
26
DELISTED
Sage Therapeutics
SAGE
| $2.42M | 1.61% |
15,495
-637
| -4% | -$100K |
2018 Q1
1 quarter
|
|
27
Armstrong World Industries
AWI
$6.84B
| $2.34M | 1.56% |
37,069
+2,831
| +8% | +$169K |
2017 Q4
2 quarters
|
|
|
28
Iovance Biotherapeutics
IOVA
$6.62B
| $2.25M | 1.49% |
+175,597
| New | +$2.57M |
2018 Q2
0 quarters
|
|
29
CBRE Group
CBRE
$37.9B
| $2.2M | 1.46% |
46,168
-720
| -2% | -$34K |
2016 Q4
6 quarters
|
|
|
ONC
30
BeOne Medicines Ltd
ONC
$40.1B
| $2.2M | 1.46% |
14,321
-4,849
| -25% | -$865K |
2017 Q1
5 quarters
|
|
31
Acadia Pharmaceuticals
ACAD
$3.41B
| $2.2M | 1.46% |
144,125
+59,411
| +70% | +$1.06M |
2015 Q1
13 quarters
|
|
|
DRNA
32
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $2.2M | 1.46% |
179,568
-66,843
| -27% | -$840K |
2018 Q1
1 quarter
|
|
|
CORI
33
DELISTED
Corium International, Inc.
CORI
| $2.2M | 1.46% |
274,651
+64,092
| +30% | +$606K |
2017 Q4
2 quarters
|
|
34
SLM Corp
SLM
$4.23B
| $2.15M | 1.43% |
+187,754
| New | +$2.17M |
2018 Q2
0 quarters
|
|
35
KALA BIO
KALA
$5.68M
| $2.12M | 1.41% |
62
-9
| -13% | -$345K |
2017 Q4
2 quarters
|
|
36
Seagate
STX
$178B
| $2.12M | 1.41% |
37,505
-3,711
| -9% | -$215K |
2016 Q4
6 quarters
|
|
37
Trinity Industries
TRN
$2.03B
| $2.1M | 1.4% |
85,232
+738
| +0.9% | +$17.8K |
2017 Q3
3 quarters
|
|
|
BPMC
38
DELISTED
Blueprint Medicines
BPMC
| $2.1M | 1.39% |
33,101
+938
| +3% | +$74.6K |
2018 Q1
1 quarter
|
|
|
DBVT
39
DBV Technologies S.A. American Depositary Shares
DBVT
$616M
| $2.1M | 1.39% |
10,868
+739
| +7% | +$167K |
2016 Q4
6 quarters
|
|
40
Citigroup
C
$217B
| $2M | 1.32% |
+29,811
| New | +$2.05M |
2018 Q2
0 quarters
|
|
41
Morgan Stanley
MS
$298B
| $1.87M | 1.24% |
39,532
+1,066
| +3% | +$55.7K |
2016 Q4
6 quarters
|
|
|
SMC
42
Summit Midstream
SMC
$440M
| $1.35M | 0.89% |
5,837
| – | – |
2016 Q4
6 quarters
|
|
43
Cocrystal Pharma
COCP
$20.6M
| $560K | 0.37% |
12,743
| – | – |
2018 Q1
1 quarter
|
|
44
Neurogene
NGNE
$528M
| $554K | 0.37% |
10,460
+1,502
| +17% | +$391K |
2016 Q4
6 quarters
|
|
45
Amazon
AMZN
$2.83T
| $269K | 0.18% |
3,160
| – | – |
2018 Q1
1 quarter
|
|
46
State Street SPDR S&P 500 ETF Trust
SPY
$833B
| $237K | 0.16% |
872
| – | – |
2017 Q4
2 quarters
|
|
47
Microsoft
MSFT
$3.97T
| – | – |
-23,505
| Closed | -$2.15M | – |
|
|
48
Puma Biotechnology
PBYI
$531M
| – | – |
-39,066
| Closed | -$2.66M | – |
|
|
49
Travere Therapeutics
TVTX
$4.91B
| – | – |
-115,136
| Closed | -$2.57M | – |
|
|
XLRN
50
DELISTED
Acceleron Pharma
XLRN
| – | – |
-62,410
| Closed | -$2.44M | – |
|
Similar funds
WH
CPW
NWS
SGM
CI
SA
SH
HA
Emory University's Q2 2018 Portfolio in Review
As of Q2 2018, Emory University held 53 positions worth $151M, up 7.6% from $140M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Emory University deployed $11.7M of net new capital in Q2 2018, opening 7 new positions and adding to 21 existing holdings. Its largest new stake was Heron Therapeutics: 84,475 shares worth $3.28M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 57% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Myovant Sciences Ltd., an estimated $1.16M trimmed.
- Emory University's largest Q2 2018 buy was Heron Therapeutics: 84,475 shares worth $3.28M.
- Emory University added most to JD.com in Q2 2018, an estimated $10.5M increase.
- Emory University's biggest Q2 2018 reduction was Myovant Sciences Ltd., cutting an estimated $1.16M.
- Emory University fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $2.78M.
- Emory University's ten largest holdings make up 49% of its $151M portfolio in Q2 2018.
- Emory University opened 7 new positions and closed 7 in Q2 2018.
- Emory University's portfolio value rose 7.6% quarter-over-quarter to $151M.
Based on Emory University's 13F filing for Q2 2018, filed 14 Aug 2018.